Beverley P C, Riethmuller G
Peter Beverley is in the ICRF Human Tumour Immunology Group, University College London, UK.
G. Riethmuller is at the Institute for Immunology of the University of Munich, FRG.
Immunol Today. 1987;8(4):101-2. doi: 10.1016/0167-5699(87)90857-7.
A recent workshop held in the Bavarian alps considered the possibilities for immunological intervention with monoclonal antibodies. While at present the benefits of most attempts to use monoclonal antibodies in vivo in man are uncertain, in-vitro and animal experiments have yielded enough positive results to encourage further efforts. Immediate dramatic effects are not to be expected because as one participant noted, we are still at an early stage in the use of monoclonal antibodies as therapeutic agents.
最近在巴伐利亚阿尔卑斯山举办的一次研讨会探讨了使用单克隆抗体进行免疫干预的可能性。目前，在人体中进行的大多数单克隆抗体体内应用尝试的益处尚不明确，但体外和动物实验已产生了足够多的积极结果，足以鼓励进一步的研究。正如一位与会者所指出的，我们不应期望会有立竿见影的显著效果，因为我们在将单克隆抗体用作治疗药物方面仍处于早期阶段。
